{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:46:47Z","timestamp":1784958407464,"version":"3.55.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"name":"Jiangsu Provincial Medical Innovation Center","award":["CXZX202215"],"award-info":[{"award-number":["CXZX202215"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>It is uncertain whether ticagrelor is more effective and safer than clopidogrel in ST-segment elevation myocardial infarction (STEMI) patients in the East Asian population in the real world. This study compared the clinical outcomes of ticagrelor and clopidogrel in STEMI patients undergoing primary percutaneous coronary intervention (PCI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively enrolled 1124 patients diagnosed with STEMI in Nanjing First Hospital from July 2011 to April 2019. Propensity score matching was used to balance baseline covariates between the ticagrelor and clopidogrel groups. The primary efficacy endpoint was all-cause death, and the primary safety endpoint was major bleeding, defined as Bleeding Academic Research Consortium type 3\u20135 bleeding.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We enrolled 1124 STEMI patients in the analysis. After propensity score matching, 420 patients were included in each group. There was a lower incidence of all-cause death in the ticagrelor group when compared with the clopidogrel group during the follow-up (8.3 vs. 17.1%; hazard ratio: 0.481; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). Ticagrelor was also associated with reduced myocardial infarction, cardiovascular death, and stent thrombosis. However, no difference was detected in major bleeding. Multivariate Cox regression analysis showed that age, Killip classification, creatinine, low-density lipoprotein, left ventricular ejection fraction, single vessel disease, inhospital intra-aortic balloon pump implantation, \u03b2-blockers, and ticagrelor were independent predictive parameters of all-cause death.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Compared with clopidogrel, ticagrelor reduced all-cause death but did not increase the incidence of major bleeding in primary PCI patients. Therefore, ticagrelor may be considered a viable substitute for clopidogrel.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001506","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T06:04:36Z","timestamp":1737525876000},"page":"e19-e25","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of ticagrelor and clopidogrel in primary percutaneous coronary intervention patients: a single-center retrospective study"],"prefix":"10.1097","volume":"36","author":[{"given":"Yufeng","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaguo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison.","volume":"72","author":"Capodanno","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/jth.12200","article-title":"Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study.","volume":"11","author":"Jeong","year":"2013","journal-title":"J Thromb Haemost"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/heartjnl-2015-308963","article-title":"Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.","volume":"102","author":"Velders","year":"2016","journal-title":"Heart"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"e012530","DOI":"10.1161\/JAHA.119.012530","article-title":"Efficacy and safety of ticagrelor in comparison to clopidogrel in elderly patients with ST-segment-elevation myocardial infarctions.","volume":"8","author":"Schmucker","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease.","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome \u2013 randomized, double-blind, phase III PHILO study.","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial.","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjcvp\/pvz048","article-title":"P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects.","volume":"6","author":"De Filippo","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/1060028017706977","article-title":"Comparative effectiveness and safety analysis of dual antiplatelet therapies within an integrated delivery system.","volume":"51","author":"Coons","year":"2017","journal-title":"Ann Pharmacother"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"e0219676","DOI":"10.1371\/journal.pone.0219676","article-title":"Antiplatelet treatment in acute coronary syndrome patients: real-world data from the START-Antiplatelet Italian Registry.","volume":"14","author":"Marcucci","year":"2019","journal-title":"PLoS One"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcma.2016.02.010","article-title":"Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: a multicenter retrospective pilot study.","volume":"79","author":"Chen","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.recesp.2017.02.007","article-title":"Safety and efficacy of prasugrel and ticagrelor in acute coronary syndrome. Results of a \u2018real world\u2019 multicenter registry.","volume":"70","author":"Almendro-Delia","year":"2017","journal-title":"Rev Esp Cardiol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials.","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2014.08.037","article-title":"Short- and long-term cause of death in patients treated with primary PCI for STEMI.","volume":"64","author":"Pedersen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"e002790","DOI":"10.1161\/CIRCOUTCOMES.116.002790","article-title":"Cardiac and noncardiac causes of long-term mortality in ST-segment-elevation acute myocardial infarction patients who underwent primary percutaneous coronary intervention.","volume":"10","author":"Yamashita","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R21-20250804","first-page":"1377","article-title":"Outcomes among clopidogrel, prasugrel, and ticagrelor in ST-elevation myocardial infarction patients who underwent primary percutaneous coronary intervention from the TOTAL trial.","volume":"35","author":"Welsh","year":"2019","journal-title":"Can J Cardiol"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"e012054","DOI":"10.1161\/JAHA.119.012054","article-title":"Comparison of in-hospital mortality and length of stay in acute ST-segment-elevation myocardial infarction among urban teaching hospitals in China and the United States.","volume":"8","author":"Han","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11886-014-0485-4","article-title":"\u2018East Asian paradox\u2019: challenge for the current antiplatelet strategy of \u2018one-guideline-fits-all races\u2019 in acute coronary syndrome.","volume":"16","author":"Jeong","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial.","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s12325-021-01907-3","article-title":"Comparison of net clinical benefit between clopidogrel and ticagrelor following percutaneous coronary intervention in patients in China with acute coronary syndrome.","volume":"39","author":"Li","year":"2022","journal-title":"Adv Ther"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000530602","article-title":"Safety and efficacy of ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome undergoing percutaneous coronary intervention treated with dual antiplatelet therapy: a meta-analysis of randomized controlled trials.","volume":"148","author":"Li","year":"2023","journal-title":"Cardiology"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ehjcvp\/pvaa002","article-title":"Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries.","volume":"7","author":"De Luca","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jcin.2016.02.013","article-title":"Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a network meta-analysis.","volume":"9","author":"Rafique","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.4244\/EIJV12I8A159","article-title":"Randomised trial to compare a protective effect of clopidogrel versus ticagrelor on coronary microvascular injury in ST-segment elevation myocardial infarction (CV-TIME trial).","volume":"12","author":"Park","year":"2016","journal-title":"EuroIntervention"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","article-title":"Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"68","author":"Tang","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijcard.2015.09.005","article-title":"Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials.","volume":"202","author":"Bulluck","year":"2016","journal-title":"Int J Cardiol"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/09537104.2020.1754381","article-title":"Ticagrelor versus clopidogrel for prevention of subclinical stent thrombosis detected by optical coherence tomography in patients with drug-eluting stent implantation \u2013 a multicenter and randomized study.","volume":"32","author":"Wu","year":"2021","journal-title":"Platelets"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"1143509","DOI":"10.3389\/fcvm.2023.1143509","article-title":"Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction.","volume":"10","author":"Yeh","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"859962","DOI":"10.3389\/fcvm.2022.859962","article-title":"Ticagrelor vs. clopidogrel in older patients with acute coronary syndrome undergoing percutaneous coronary intervention: insights from a real-world registry.","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/CIA.S355210","article-title":"Comparison of clinical outcomes between ticagrelor and clopidogrel in elderly patients undergoing percutaneous coronary intervention: a cohort study.","volume":"17","author":"Meng","year":"2022","journal-title":"Clin Interv Aging"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2022.01.019","article-title":"Net clinical benefit of different strategies of dual antiplatelet therapy in elderly patients: data from the praise registry.","volume":"353","author":"D\u2019Ascenzo","year":"2022","journal-title":"Int J Cardiol"},{"key":"R37-20250804","doi-asserted-by":"crossref","first-page":"887748","DOI":"10.3389\/fcvm.2022.887748","article-title":"Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: an on-treatment analysis from a multicenter registry.","volume":"9","author":"Almendro-Delia","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R38-20250804","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jacc.2019.03.011","article-title":"Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: TREAT trial.","volume":"73","author":"Berwanger","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:00:29Z","timestamp":1754323229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001506","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}